A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
Phase of Trial: Phase III
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Depression; Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms SUSTAIN-1
- Sponsors Janssen Research & Development
- 07 Sep 2017 Planned primary completion date changed from 17 Aug 2017 to 30 Apr 2018.
- 02 May 2017 Planned End Date changed from 1 Apr 2019 to 30 Apr 2018.
- 25 Nov 2016 Planned End Date changed from 1 Aug 2018 to 1 Apr 2019.